Asset
Ersodetug
Rezolute Inc. Common Stock (NV)
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06208215 | phase3 | active_not_recruiting | 2024-01-11 | 2025-11-14 | Rezolute | RZ358 Treatment for Congenital Hyperinsulinism |
FDA applications (0)
This company has no applications containing this asset.